ストックスクリーナーアプリを入手
0.403
2.52%
0.0099
プレマーケット:
.40
-0.003
-0.74%
Vivos Therapeutics Inc (VVOS) 最新ニュース
Vivos Therapeutics Inc (VVOS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vivos Therapeutics Inc (VVOS) Institutional Confidence - TradingKey
Vivos Therapeutics Inc (VVOS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vivos Therapeutics, Inc. Revenue Breakdown – NASDAQ:VVOS - TradingView
Vivos Therapeutics Inc (VVOS) Balance Sheet - TradingKey
TradingKey - TradingKey
Vivos Therapeutics Inc (VVOS) Cash Flow - TradingKey
Vivos Therapeutics Inc (VVOS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
VVOS|Vivos Therapeutics Inc|Price:0.393|Chg%:+0.003 - TradingKey
VVOS|Vivos Therapeutics Inc|Price:0.395|Chg%:+0.002 - TradingKey
Vivos Therapeutics Inc (VVOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
VVOS|Vivos Therapeutics Inc|Price:0.409|Chg%:+0.016 - TradingKey
Vivos Therapeutics Inc (VVOS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vivos Therapeutics (VVOS) Holds Near Support as Micro-Cap Stock Shows Measured MovementVolatility Breakout Picks - dars.gov.et
Vivos Therapeutics (VVOS) Edges Higher, Testing Key Resistance Near $0.44Dynamic Hedging - dars.gov.et
Vivos Therapeutics (VVOS) Stock Fair Value Falls After Analyst Target Cuts - Yahoo Finance
Vivos Therapeutics (VVOS) Holds Steady at $0.41, Support Level in FocusFear Greed Index - dars.gov.et
Vivos Therapeutics Inc. (VVOS) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Form 4 Vivos Therapeutics Inc For: 15 July By Investing.com - Investing.com Nigeria
Michael C. Skaff Discloses Investment at Vivos Therapeutics with 19.9% Stake - TradingView
Investor group takes 19.9% position in Vivos Therapeutics (VVOS) - Stock Titan
Vivos Therapeutics (NASDAQ: VVOS) insider entity buys 5.5M derivatives - Stock Titan
Vivos Therapeutics (NASDAQ: VVOS) holder discloses warrant and preferred stake - Stock Titan
Price to earnings forward of Vivos Therapeutics, Inc. – NASDAQ:VVOS - TradingView
Vivos Therapeutics (VVOS) Slides 6.87% as Bearish Pressure Tests Critical SupportLate Stage Breakouts - DonanımHaber
A. G. P. Maintains Vivos Therapeutics(VVOS.US) With Hold Rating, Cuts Target Price to $0.75 - Moomoo
Vivos Therapeutics Announces Securities Purchase Agreement and Registration Rights for PIPE Financing - Minichart
Vivos Therapeutics Creates New Series A Preferred Stock - TipRanks
Vivos Therapeutics Raises $2.1 Million in PIPE With V-Co 4 and Bigger Capital - TradingView
Vivos Therapeutics (VVOS) completes $2.1M PIPE with preferred stock and warrants - Stock Titan
Vivos Therapeutics (VVOS) Holds Near Support Amid Modest Decline – Key Levels in FocusMFI Overbought - dars.gov.et
Enterprise value to EBITDA forward of Vivos Therapeutics, Inc. – NASDAQ:VVOS - TradingView
VVOSVivos Therapeutics Inc Latest SEC Filings - Finviz
Vivos Therapeutics (VVOS) Stock Sees Fair Value Moves Lower As Analysts Reset Growth Assumptions - Yahoo Finance
12 Health Care Stocks Moving In Tuesday's After-Market SessionAlzamend Neuro (NASDAQ:ALZN), Vivos Ther - Benzinga
Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants - The Manila Times
Vivos Therapeutics, Inc. announced that it has received $1 million in funding - marketscreener.com
VIVOS THERAPEUTICS INC (VVOS) Stock Chart - ChartMill
Vivos Therapeutics, Inc. Actuals & Estimates (NASDAQ:VVOS) - TradingView
Vivos Therapeutics Extends Debt-for-Equity Conversion Timeline - TipRanks
Vivos (NASDAQ: VVOS) extends Streeterville $4.5M debt-for-equity pact - Stock Titan
Vivos Therapeutics Enters Debt-for-Equity Deal, Extends $2.6M Financing Deadline With Streeterville - TradingView
VVOS Forecast — Price Target — Prediction for 2027 - TradingView
VVOS Q1 2026 Earnings: EPS Misses Estimates as Stock Surges on Operational ProgressOne-Time Gain Impact - Bölüm Sonu Canavarı
Vivos extends debt conversion deadline with Streeterville to August - Investing.com UK
Vivos extends debt conversion deadline with Streeterville to August By Investing.com - Investing.com Australia
Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity - marketscreener.com
Vivos gets more time to convert $4.5M debt into equity - Stock Titan
VVOS Should I Buy - Intellectia AI
Vivos Therapeutics Inc (VVOS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vivos Therapeutics Inc (VVOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
0.79%
4.39%
大文字化:
|
ボリューム (24 時間):